Targets › CLDN1
1 program from 1 company in 1 trial: 1 Phase 2; Genitourinary; next expected readout Jun 2027.
Claudins function as major constituents of the tight junction complexes that regulate the permeability of epithelia. While some claudin family members play essential roles in the formation of impermeable barriers, others mediate the permeability to ions and small molecules. (UniProt, O95832)
Open in Phaseline: the race on CLDN1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Alentis Therapeutics | ALE.F02 anti-CLDN1 monoclonal antibody targeting non-tight junction exposed form | CLDN1 | Phase 2 | Glomerulonephritis Rapidly Progressive | Jun 2027 |
Glomerulonephritis Rapidly Progressive (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.